Edwards Lifesciences Files Official Comment on CMS' Proposed TAVR National Coverage Determination
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, reported that on March 3, 2012, the company filed its official response to the Centers for Medicare & Medicaid Services (CMS) on its Proposed National Coverage Determination (NCD) for Transcatheter Aortic Valve Replacement (TAVR).
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.